This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sodium cromoglicate ocular


Sodium cromoglicate eye drops preservative containing.

Drugs List

  • ALLERGY RELIEF 2% eye drops
  • HAYFEVER RELIEF 2% eye drops
  • MURINE HAYFEVER 2% eye drops
  • OPTICROM ALLERGY 2% eye drops
  • OPTICROM AQUEOUS eye drops
  • OPTICROM HAYFEVER 2% eye drops
  • OPTREX ALLERGY EYES 2% aqueous eye drops
  • sodium cromoglicate 2% eye drops
  • Therapeutic Indications


    Seasonal and perennial allergic conjunctivitis



    Instil one or two drop(s) into each affected eye up to four times daily, or as indicated by the physician.


    Instil one or two drop(s) into each affected eye up to four times daily, or as indicated by the physician.

    Not all brands are licensed for children under 6 years.


    None known

    Precautions and Warnings

    Children under 6 years
    Soft contact lenses

    Advise patient blurred vision may affect ability to drive/operate machinery
    Not all available brands are licensed for all indications
    Not all available brands are licensed for use in children under 6 years
    Contains benzalkonium chloride
    Discard any remaining solution 28 days after opening
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Advise patient to avoid touching the eye/other surfaces with container tip
    Advise patient to seek medical advice if treatment is ineffective
    If soft contact lenses worn,insert them 15 minutes after using eye drops

    Pregnancy and Lactation


    Use sodium cromoglicate eye drops with caution in pregnancy.

    The manufacturer notes that this medication should only be considered if the expected benefit to the mother is greater than any risk to the foetus.

    Cumulative experience suggests that sodium cromoglicate has no adverse effects on foetal development.


    Sodium cromoglicate eye drops are considered safe to use in breastfeeding.

    The manufacturer notes that it is unknown if sodium cromoglicate is excreted into human breast milk but on the basis of its physio-chemical properties, this is considered unlikely.

    There is little information to suggest that the use of sodium cromoglicate has any undesirable effects on the baby.

    Side Effects

    Blurred vision (transient)
    Burning sensation (local)
    Irritation (localised)
    Stinging (transient)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2019

    Reference Sources

    Summary of Product Characteristics: Allergy Relief 2% w/v eye drops, solution; Optrex Allergy 2% w/v Eye Drops, Solution; Opticrom Allergy 2% Eye Drops, Solution. Aspire Pharma Limited. Revised March 2018.

    Summary of Product Characteristics: Opticrom Aqueous 2% w/v Eye Drops, solution. Aspire Pharm Limited. Revised November 2018.

    Summary of Product Characteristics: Polenase Hayfever Relief 2% w/v Eye Drops, solution. Aspire Pharm Limited. Revised August 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.